A comparison of dyslipidemias associated with either lopinavir/ritonavir- or indinavir/ritonavir-based antiretroviral therapy

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1666-7. doi: 10.1097/00126334-200412150-00023.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Letter

MeSH terms

  • Adult
  • CD4 Lymphocyte Count
  • Cholesterol / blood
  • Cohort Studies
  • Drug Therapy, Combination
  • Dyslipidemias / chemically induced*
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Protease Inhibitors / adverse effects*
  • HIV Protease Inhibitors / therapeutic use
  • Humans
  • Indinavir / adverse effects*
  • Indinavir / therapeutic use
  • Lopinavir
  • Pyrimidinones / adverse effects*
  • Pyrimidinones / therapeutic use
  • Retrospective Studies
  • Ritonavir / adverse effects*
  • Ritonavir / therapeutic use
  • Treatment Outcome
  • Triglycerides / blood
  • Viral Load

Substances

  • HIV Protease Inhibitors
  • Pyrimidinones
  • Triglycerides
  • Lopinavir
  • Indinavir
  • Cholesterol
  • Ritonavir